Despite significant advances in battery longevity, lead performance, and programming features since the first implanted permanent pacemaker was developed, the basic design of cardiac pacemakers has remained relatively unchanged over the past 50 years. Because of inherent limitations in their design, conventional (transvenous) pacemakers are prone to multiple potential short-and long-term complications. Accordingly, there has been intense interest in a system able to provide the symptomatic and potentially lifesaving therapies of cardiac pacemakers while mitigating many of the risks associated with their weakest link-the transvenous lead. Leadless cardiac pacing represents the future of cardiac pacing systems, similar to the transition that occurred from the use of epicardial pacing systems to the familiar transvenous systems of today. This review summarizes the current evidence and potential benefits of leadless pacing systems, which are either commercially available (in Europe) or under clinical investigation. (J Am Coll Cardiol 2015;66:1179-89) 
Recently, the results of WiSE-CRT (Wireless Stimulation Endocardially for CRT), a prospective observational feasibility study of leadless ultrasound-based endocardial left ventricular pacing in patients with guideline-directed indication for cardiac resynchronization therapy (CRT) were reported (12) . The
WiSE-CRT study used a system intended for chronic use with 2 components: a subcutaneous pulse generator and a small receiver electrode. The subcutaneous pulse generator was surgically implanted in the left lateral thorax (subcutaneous) and generated ultrasonic acoustic energy; the small receiver electrode was implanted directly onto the left ventricular endocardium (using a retrograde aortic approach) and converted the acoustic energy to electric pacing pulses (13) . All patients in WiSE-CRT had existing implantable cardiac devices (pacemakers or defibrillators) and were considered eligible for enrollment if they: 1) had undergone prior failed coronary sinus lead implantation; 2) had undergone previously successful placement of a coronary sinus lead but were clinical nonresponders; or 3) required an upgrade to a CRT system (12, 14) .
From an efficacy perspective, the results of WiSE- After WiSE-CRT was terminated because of safety concerns, the delivery system was redesigned to permit atraumatic implantation of the receiver electrode onto the left ventricular endocardial surface.
Similar to that studied in WiSE-CRT, the redesigned leadless system is also composed of an implanted battery-powered ultrasonic transmitter and a leadless pacing electrode implanted directly onto the left ventricular endocardium (Figure 1) . Again, the system detects a right ventricular pacing pulse from a coimplanted pacemaker or defibrillator and delivers ultrasonic energy to the electrode, which transduces the energy to an electric pacing pulse to stimulate the left ventricle synchronously with the right ventricle.
The initial evaluation of this redesigned system in the In subsequent cases, oral anticoagulation was not interrupted (at operator discretion) for the procedure, and no subsequent strokes were observed; however, the safety of this strategy needs to be validated in a larger cohort of patients. However, it should be noted that in a study that used a different approach to left ventricular endocardial pacing (using a transseptal approach), 14% patients ( Anteroposterior (AP) (A) and lateral (LAT) (B) chest radiograph views of the implanted system, including battery, transmitter, and receiver/ pacing electrode (inset).
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S E P T E M B E R
INDUCTION TECHNOLOGY. Leadless pacing using induction (electromagnetic) technology also consists of at least 2 components: a subcutaneous (or submuscular) transmitter unit located just above the heart and a receiver unit implanted into the ventricular endocardium (25) . Briefly, the transmitter generates an alternating magnetic field, of which a fraction is converted to stimulatory voltage pulses by the receiver unit. Although leadless pacing using induction may be feasible, it has been tested only in animal models (porcine and goat), and further work is needed to determine the effects of alignment, distance, and external interferences on this technology (26) . Figure 2 , and the 2 devices are compared in Table 1 .
SINGLE-COMPONENT (FULLY SELF-CONTAINED) LEADLESS PACING
With regard to fixation mechanisms, the LCP uses an active screw-in helix and a secondary fixation mechanism consisting of 3 angled nitinol tines perpendicular to the helix, whereas the TPS uses 4
self-expanding nitinol tines to affix to the myocardium. Figure 3 shows an example of an implantation of an LCP that was repositioned acutely prior to being disconnected from the delivery catheter; it was then FI GURE 2 The Single-Component (Fully Self-Contained) Leadless Pacemakers
The Micra Transcatheter Pacing System (left) and Nanostim leadless cardiac pacemaker (right) are shown next to a ruler.
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positioned at an alternative apical septal location to achieve stable and durable sensing and pacing parameters. Figure 4 shows an example of the protective sleeve, fixation mechanism, and bipolar sensing and pacing configuration of the TPS. Both devices use a tethering mechanism to maintain a connection between the delivery catheter and the device to test positional integrity before final deployment. Figure 5 shows an example of a TPS implantation. Finally, both devices are reportedly retrievable, although only animal data with the LCP exist to demonstrate the feasibility of chronic extraction. Figure 6 shows fluo- One of the most important determinants of battery Miller et al. vivek.reddy@mountsinai.org.
